The present paper reportsan exceedingly rare presentation of AMI in a very young maleassociated with acute myopericarditis treatment.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Patients aged less than 40 years old only account for 1.2% ofall patients with acute myocardial infarction (AMI) (1).
📊
Key Findings & Data:Severalstudies as well as meta-analyses have revealed that the use ofnon-steroidal anti-inflammatory drugs (NSAIDs) can be associated with an increased relative risk of AMI in patients with orwithout heart disease or other risk factors for coronary arterydisease (2-7).
💡
Conclusion & Impact:The present paper reportsan exceedingly rare presentation of AMI in a very young maleassociated with acute myopericarditis treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Patients aged less than 40 years old only account for 1.2% ofall patients with acute myocardial infarction (AMI) (1). Severalstudies as well as meta-analyses have revealed that the use ofnon-steroidal anti-inflammatory drugs (NSAIDs) can be associated with an increased relative risk of AMI in patients with orwithout heart disease or other risk factors for coronary arterydisease (2-7). Diclofenac and ibuprofen, the most frequentlyused NSAIDs, are associated with a 40%–50% increased relative risk of AMI, even for low cumulative NSAID amounts (8). TheAMI risk in patients with and without cardiovascular risk factors showed a similar elevation (8). The present paper reportsan exceedingly rare presentation of AMI in a very young maleassociated with acute myopericarditis treatment.
🔖
Cite This Article
KURTUL, A., ŞEN, H. F., BEKLER, Ö. (2020). Acute anterior myocardial infarction during myopericarditis treatment in a very young adult. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 6, 353–359. https://ajindex.com/articles/365220
Trzeciak P, Gierlotka M, Gąsior M, Osadnik T, Hawranek M, Lekston A, et al. In-hospital and 12-month outcomes after acute coronary syndrome treatment in patients aged 2. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266-74. 3. García Rodríguez LA, González-Pérez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005; 3: 17. 4. Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Klaukka T, Idänpään-Heikkilä JE, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27: 1657-63. 5. Bally M, Beauchamp ME, Abrahamowicz M, Nadeau L, Brophy JM. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf 2018; 27: 69-77. 6. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086. 7. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013; 22: 559-70. 8. Thöne K, Kollhorst B, Schink T. Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case-Control Study. Drugs Real World Outcomes 2017; 4: 127-37. 9. Martínez-González J, Badimon L. Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007; 13: 2215-27.